What is FBLG's current stock price?

FBLG (FibroBiologics, Inc. Common Stock) is currently trading at $1.05 with a market cap of $2.2M.

What sector is FibroBiologics, Inc. Common Stock in?

FibroBiologics, Inc. Common Stock (FBLG) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is FBLG a good stock to buy?

Analysts have a Hold consensus on FBLG with a price target of $180.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

FBLG FibroBiologics, Inc. Common Stock

Healthcare

$1.05+0.00%ClosedMarket Cap: $2.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.90

P/S

0.00

EV/EBITDA

-0.17

DCF Value

$1.11

FCF Yield

-713.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-767.1%

ROA

-314.6%

ROIC

-355.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.0M	$—
Q4 null	$0.00	$-3.2M	$—
FY null	$0.00	$-18.6M	$—
Q3 null	$0.00	$-5.8M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$180.00

Target (Median)

$180.00

Target Range

$180.00 - $180.00

1 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell

Maxim GroupHold

2026-05-04

HC Wainwright & Co.Buy

2026-04-16

D. Boral CapitalHold

2026-03-26

D. Boral CapitalBuy

2026-03-12

HC Wainwright & Co.Buy

2026-02-26

Trading Activity

Insider Trades

View All

O'HEERON PETEdirector, officer: CHIEF EXECUTIVE OFFICER

SellMon May 04

Khoja Hamidofficer: Chief Scientific Officer

SellMon May 04

GARCIA RUBEN Aofficer: General Counsel

SellMon May 04

Davis Jasonofficer: Chief Financial Officer

SellMon May 04

Khoja Hamidofficer: Chief Scientific Officer

BuyThu Mar 05

Latest News

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Thu Apr 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.10

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Peers

ICU